Computational-based drug repurposing methods in COVID-19

[Image: see text] COVID-19, as a newly emerging disease, has disrupted human’s different activities. Hence, it is essential to develop drugs or vaccines in order to control COVID-19. Since there is not a medication or vaccine for treating the disease and drug development project is a time and cost c...

Descripción completa

Detalles Bibliográficos
Autor principal: Masoudi-Sobhanzadeh, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416005/
https://www.ncbi.nlm.nih.gov/pubmed/32793443
http://dx.doi.org/10.34172/bi.2020.25
_version_ 1783569240656183296
author Masoudi-Sobhanzadeh, Yosef
author_facet Masoudi-Sobhanzadeh, Yosef
author_sort Masoudi-Sobhanzadeh, Yosef
collection PubMed
description [Image: see text] COVID-19, as a newly emerging disease, has disrupted human’s different activities. Hence, it is essential to develop drugs or vaccines in order to control COVID-19. Since there is not a medication or vaccine for treating the disease and drug development project is a time and cost consuming process, drug repurposing approaches may yield to proper curing plans. However, there are some limitations in this field, which make the process a challenging one. This letter aims to introduce drug repurposing methods and the existing challenges to detect candidate drugs which may be helpful in controlling COVID-19.
format Online
Article
Text
id pubmed-7416005
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Tabriz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-74160052020-08-12 Computational-based drug repurposing methods in COVID-19 Masoudi-Sobhanzadeh, Yosef Bioimpacts Letter to the Editor [Image: see text] COVID-19, as a newly emerging disease, has disrupted human’s different activities. Hence, it is essential to develop drugs or vaccines in order to control COVID-19. Since there is not a medication or vaccine for treating the disease and drug development project is a time and cost consuming process, drug repurposing approaches may yield to proper curing plans. However, there are some limitations in this field, which make the process a challenging one. This letter aims to introduce drug repurposing methods and the existing challenges to detect candidate drugs which may be helpful in controlling COVID-19. Tabriz University of Medical Sciences 2020 2020-06-18 /pmc/articles/PMC7416005/ /pubmed/32793443 http://dx.doi.org/10.34172/bi.2020.25 Text en © 2020 The Author(s) This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Letter to the Editor
Masoudi-Sobhanzadeh, Yosef
Computational-based drug repurposing methods in COVID-19
title Computational-based drug repurposing methods in COVID-19
title_full Computational-based drug repurposing methods in COVID-19
title_fullStr Computational-based drug repurposing methods in COVID-19
title_full_unstemmed Computational-based drug repurposing methods in COVID-19
title_short Computational-based drug repurposing methods in COVID-19
title_sort computational-based drug repurposing methods in covid-19
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416005/
https://www.ncbi.nlm.nih.gov/pubmed/32793443
http://dx.doi.org/10.34172/bi.2020.25
work_keys_str_mv AT masoudisobhanzadehyosef computationalbaseddrugrepurposingmethodsincovid19

Ejemplares similares